ArticleJMA journal2026
Qualitative and Quantitative Estimation of Ceftriaxone in Pharmaceutical Dosage Forms Using Reverse Phase High Performance Liquid Chromatography.
Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As the "pharmacy of the world," India plays a critical role in global pharmaceutical supply. However, increasing reports of substandard and falsified medicines raise serious concerns. With Jammu and Kashmir witnessing repeated quality failures of ceftriaxone, this study aims to verify its quality using a refined high-performance liquid chromatography (HPLC)-based analytical method. Methods: The ceftriaxone assay was performed using Agilent 1260 Infinity HPLC System with a C18 column and EZChromS1 software. A solvent system of acetonitrile and water (20:80, v/v) was used, with flow rate of 0.5 mL/min and ultraviolet detection at 254 nm. Standard solutions (20-70 μg/mL) were prepared from a 1,000 μg/mL stock for calibration. Nineteen injectable ceftriaxone brands were procured and coded for anonymity. Sample solutions were prepared at 50 μg/mL. The method was validated as per International Council for Harmonisation (ICH) guidelines for accuracy, precision, linearity, specificity, limit of detection (LOD), limit of quantification (LOQ), and robustness. Solution stability was assessed over 7 days at 2°C-8°C. Results: The developed isocratic reversed-phase HPLC method showed good linearity (R Conclusions: A simple, sensitive, and cost-effective HPLC method was developed and validated for estimation of ceftriaxone in pharmaceutical dosage forms. Among 19 tested formulations, 89.5% complied with Indian Pharmacopoeial standards, while two formulations were found substandard, indicating variability in product quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.